STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell

Sarepta said its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial.
Click here to view original post